NIDEK 2000 EC-5000 EXCIMER LASER SYSTEM

{0} # Summary of Safety and Effectiveness Data # I. GENERAL INFORMATION | Device Generic Name: | Ophthalmic Excimer Laser System | | --- | --- | | Device Trade Name: | Nidek EC-5000 Excimer Laser System | | Device ProCode: | LZS | | Applicant's Name and Address: | Nidek Co. LTD 34-14 Maehama Hiroishi-cho Gamagori, Aichi Japan 443-0038 | | Date of Panel Recommendation: | None | | Premarket Approval Application (PMA) Number: | P970053/S011 | | Date of FDA Notice of Approval: | September 30, 2013 | The Nidek EC-5000 CX Excimer Laser System was originally approved on December 17, 1998 under PMA P970053 for the limited indication for myopic photorefractive keratectomy (PRK) uncomplicated by astigmatism (≤ -0.75 D) in patients 21 years of age or older with -0.75 to -13.0 D of myopia whose refractive change for one year prior to treatment is within ±0.5 D for low myopia (≤ -7.0 D MRSE) or within ± 1.0 D for high myopia (> -7.0 D MRSE). For more information, please see our website at: http://www.accessdata.fda.gov/cdrh_docs/pdf/P970053b.pdf. The clinical indication was expanded in Supplement 1 (approved September 29, 1999) to include PRK treatment of myopic astigmatism (-1.00 to -8.00 D MRSE with -0.5 to -4.00 D cylinder). Supplement 6 (approved September 4, 2001) further expanded the clinical indication to include laser assisted in-situ keratomilieusis (LASIK) for the treatment of myopic astigmatism (-1.00 to -14.00 D MRSE with up to -4.00 D astigmatism) using an optical zone between 5.0 and 6.5 mm in patients 21 years of age or older. Supplement 9 further expanded the clinical indication to include hyperopia and hyperopic astigmatism PMA P970053/S11 FDA Summary of Safety and Effectiveness Data Page 1 {1} (+0.5 D to +5.00 D with up to +2.00 D astigmatism and up to +5.00 D MRSE). Supplement 11 further expands the approved clinical indications to custom topography-assisted LASIK treatments. The clinical data to support the expanded indication are provided in this summary. ## II. INDICATIONS FOR USE The Nidek EC-5000 Excimer Laser System is indicated for topography-assisted Laser-Assisted In-Situ Keratomileusis (LASIK) treatment using the Final Fit™ custom ablation treatment planning software: - for the reduction or elimination of myopic refractive errors from -1.0 to -4.0 D of sphere with astigmatic refractive errors from >-0.5 to -2.0 D at the spectacle plane with manifest refraction spherical equivalent (MRSE) of >-1.0 to -5.0 D; - in patients 21 years of age or older; and, - in patients with documented stability of manifest refraction over the prior year, demonstrated by a change in MRSE not greater than ±0.5 D. ### III. CONTRAINDICATIONS LASIK surgery is contraindicated in: - Patients with severe dry eye; - Patients with recurrent corneal erosion; - Patients with advanced Glaucoma; - Patients with collagen vascular, autoimmune or immunodeficiency diseases; - Pregnant or nursing women; - Patients with signs of keratoconus, keratoconus suspect, or unstable central keratometry readings with irregular mires; - Uncontrolled Diabetes; - Eyes that have a calculated residual stromal bed thickness that is less than 250 microns; or - Eyes for which a preoperative OPDScan that contains the torsional error detection measurements for eye orientation cannot be obtained. - Patients with uncontrolled eye movements (nystagmus) or another condition that prevents a steady gaze. ### IV. WARNINGS AND PRECAUTIONS PMA P970053/S11 FDA Summary of Safety and Effectiveness Data Page 2 {2} The warnings and precautions can be found in the device labeling. # V. DEVICE DESCRIPTION The Nidek EC-5000 Excimer Laser System is an ophthalmic laser system for refractive surgery of the cornea designed to correct the vision of patients with a variety of refractive errors (myopia, myopic astigmatism, hyperopia, and hyperopic astigmatism). The EC-5000 System consists of an argon fluoride (ArF) excimer laser and beam delivery system, a diode aiming laser; the laser optical viewing system including the microscope, fixation light, and illumination lamps; the mechanical systems used for positioning, focusing, and gas handling; and microprocessor controllers. The EC-5000 Excimer uses a 193 nm ArF laser beam to recontour the cornea by ablation of corneal tissue using a scanning beam delivery system. The Nidek EC-5000 Excimer Laser System is identical to the marketed version approved under P970053 for LASIK with the exception that the Nidek EC-5000 now includes additional software, called Final Fit™. This simulation software uses corneal topography data obtained from the OPD-Scan Model ARK-1000 aberrometer device to simulate the postoperative corneal shape and generate shot data to perform the simulated ablation. Minor asymmetric irregularities detected in the corneal topography data can be treated using the Multipoint Ablation Module feature on the EC-5000 Excimer Laser System. The Final Fit™ simulation software has three simulation modes available to the approved EC-5000 System: - **Spherical Ablation:** This is the traditional technique that uses sphere, cylinder, and axis to determine the amounts of spherical and cylindrical ablations. The optical zone (OZ) is ablated as a spherical lens. - **Optimized Aspheric Treatment Zone Ablation (OATz):** This ablation mode is different than the spherical mode in that the treatment zone (TZ) area that lies between the outer edge of the optical zone and the outermost area of the entire ablation zone, is adjustable, based on the diameter of the OZ and TZ that are selected. In the TZ, the amount of ablation gradually decreases in such a manner that this outer TZ is very smooth with no abrupt changes in curvature. This contributes to a reduction in nighttime glare and halo that can result from abrupt curvature changes. - **Customized Aspheric Treatment Zone Ablation (CATz):** This ablation mode consists of the performance of an OATz ablation plus the performance of an additional ablation using the Multipoint Ablation Module to treat the corneal irregularities detected by corneal topography. PMA P970053/S11 FDA Summary of Safety and Effectiveness Data Page 3 {3} The Final Fit™ software allows the user to select one of the three available simulation modes. Corneal irregularities can be treated in the CATz mode using the Multipoint Ablation Module feature of the EC-5000 Excimer Laser, which consists of a linear arrangement of six different 1 mm beams that can be used independently or together to provide localized ablation patterns. Shot data can be generated from the Final Fit™ software using diagnostic data from the Nidek OPD-Scan (Refractive Power/Corneal Analyzer ARK-10000) and Final Fit™ simulation software. The Final Fit™ software accepts the measurement data from the OPD-scan device via a floppy disk. These data are then used to simulate the postoperative topography using the approved optical zone and treatment zone diameters and the #5 CATz treatment zone profile. CATz treatment uses the preoperative corneal shape as the basis of ablation algorithms. Once the treatment parameters are selected, the software creates the operation data (shot file) by calculating the difference between the preoperative corneal shape and the desired postoperative corneal shape. The Final Fit™ software is loaded on a stand-alone computer. If the CATz mode is selected, the shot file that is created is separated into three parts: sphere, cylinder, and irregularity. The scanning slit of the NIDEK-EC-5000 corrects the spherical and cylindrical components in its usual fashion using the selected OATz profile followed by the irregularity treatment using the Multipoint Ablation Module. Final Fit™ software can be used to generate CATz treatment plans for the treatment of myopic astigmatism with the following parameters that are operational in the approved system: - OATz profile #5 - Optical Zone = 5.0 mm - Manifest Cylinder -0.5 to -2.0 D - Manifest Sphere -1.0 to -4.0 D - Torsion Error Detection (TED) data are present on the preoperative OPD-Scan topography that is used for treatment simulation and planning # Nidek EC-5000 Laser Specifications | Model | EC-5000 (Model EC2B) | | --- | --- | | Pulse Repetition Rate | 40 Hz | | Fluence (nominal) | 300 mJ/cm²/scan (mean at the cornea) | | Slit Beam | 2 mm by 10 mm (FWHM) | | Iris Diaphragm Diameter | 10 mm (Max) | | Multipoint Segmental Unit | linear array of six 1 mm spot beams (1.8 mm center-to-center spacing on the cornea) | | Optical Zone/Ablation Zone | 5.0 mm/8.5 mm (spherocylindrical) | | | 6.0 mm/8.5 mm (irregularity) | | Ablation Rate in Cornea | 0.6 μm/scan | | Ablation Rate in PMMA | 0.315 μm/scan | The software versions in the laser system are as follows: PMA P970053/S11 FDA Summary of Safety and Effectiveness Data Page 4 {4} | Laser Operating System | Windows 2000 v.5.26(a) | | --- | --- | | 200 Hz Eye tracker | ETC v.4.10 | | Dragon Eye Software | v.3.20 | | --- | --- | | Final Fit™ Software | v.1.11 | ## **VI. ALTERNATIVE PRACTICES AND PROCEDURES** Alternative methods of correcting nearsightedness (myopia) with astigmatism include: glasses, contact lenses, surface procedures such as photorefractive keratectomy (PRK), LASIK, and phakic IOLs approved within the same refractive range. ## **VII. MARKETING HISTORY** The EC-5000 Excimer Laser System has been distributed worldwide in more than 50 countries including Algeria, Argentina, Australia, Bahrain, Belgium, Bolivia, Brazil, Canada, Chile, China, Costa Rica, Croatia, Czech Republic, Dominican Republic, Ecuador, Egypt, Finland, France, Germany, Greece, India, Indonesia, Iran, Ireland, Israel, Italy, Korea, Kuwait, Japan, Jordan, Lebanon, Malaysia, Mexico, New Zealand, Oman, Norway, Pakistan, Paraguay, Peru, Poland, Puerto Rico, Romania, Russia, Saudi Arabia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Syria, Taiwan, Thailand, Tunisia, Turkey, UAE, UK, Ukraine, United States, Uruguay, and Venezuela. The Nidek EC-5000 Excimer Laser System has not been withdrawn from any country or market for reasons of safety or effectiveness. ## **VIII. POTENTIAL ADVERSE EFFECTS OF THE DEVICE ON HEALTH** Below is a list of the potential adverse effects (e.g., complications) associated with the use of the device. Potential adverse effects associated with LASIK include: loss of best spectacle-corrected visual acuity (BSCVA), double vision, sensitivity to bright lights, difficulty with night vision, fluctuations in vision, increased intraocular pressure, corneal haze, secondary surgical intervention, corneal infiltrate or ulcer, corneal epithelial defect, corneal edema, problems associated with the flap including a lost, misplaced, or misaligned flap, and retinal vascular accidents. For the specific adverse events that occurred in the clinical study, see Section X below. PMA P970053/S11 FDA Summary of Safety and Effectiveness Data Page 5 {5} # IX. SUMMARY OF PRECLINICAL STUDIES # A. Laboratory/Animal Studies No preclinical in-vivo studies were conducted or required to demonstrate safety and effectiveness. # B. Additional Studies # 1. Hazard Analysis and Software Validation Hazard analysis and software validation testing were conducted for the Nidek EC-5000 Excimer Laser System, including the MultiPoint Ablation module and the Windows-based system operating software, and the Final Fit™ custom treatment planning software. The hazard analysis includes risk assessment of hazards to the patient, operator, service personnel, bystanders, manufacturing personnel, and the environment. The software validation procedures covered all aspects of new software specifications and design, development, testing, functionality and performance. The hazard analysis and software validation testing indicated no new hazards affecting safety or effectiveness. Refer to the EC-5000 Excimer Laser System Operator's Manual, MultiPoint Ablation Module Operator's Manual, and the Final Fit™ Operator's Manual for safety precautions for the use of the excimer laser system and the Final Fit™ system. # 2. Profilometry of Ablation As a part of this PMA, Nidek validated the accuracy of the myopic astigmatic corrections by performing a variety of test ablations on flat and curved plastic surfaces. All ablations were scanned with a surface profilometer or the OPDScan corneal analyzer and showed good agreement to theoretical targets. # X. SUMMARY OF PRIMARY CLINICAL STUDY The applicant performed a clinical study to establish a reasonable assurance of safety and effectiveness of topography-guided LASIK treatment with the Nidek EC-5000 Excimer Laser System using the Customized Aspheric Treatment Zone (CATz) mode of Final Fit™ custom treatment planning software for the correction of myopia with astigmatism was conducted under IDE G040194 in the United States (3 sites) and Mexico (1 site). Safety and effectiveness outcomes at 3 months postoperatively were assessed, as refractive stability is reached by that time. Data from this clinical study were the basis for the PMA approval. PMA P970053/S11 FDA Summary of Safety and Effectiveness Data Page 6 {6} ## A. Study Design Subjects were treated between December 14, 2005 and September 28, 2006. The database for this PMA submission reflects postoperative visits completed through May 15, 2008 and includes clinical data for 136 enrolled and 135 treated eyes. On December 18, 2007, in response to IDE G040194/S009, FDA approved study termination subject follow up at the 12-month postoperative visit instead of the 24-month visit. This contributed to a limited number of 18 and 24-month postoperative visits available for reporting. Four investigational sites provided eligible data for analysis. This was a prospective, non-randomized, open-label, multi-center study in which the control was the preoperative state of the treated eye (i.e., comparison of pretreatment and post-treatment visual parameters in the same eye). The objective of this clinical study was to demonstrate that topography-guided LASIK treatment with the Nidek EC-5000 and Final Fit™ treatment planning software is safe and effective for the correction of myopia with astigmatism. The sample size for this study was based on having a high probability the confidence interval for the mean refractive error is wholly contained in the interval (-0.5D, 0.5D). A sample size of 125 evaluable eyes was deemed sufficient to estimate the mean refractive error to within $\pm 0.5$ D. Since historically there is a 10% discontinuation rate, the sample size was adjusted for a 10% rate of discontinued and lost-to-follow-up eyes. The adjusted sample size calculations accounting for this 10% lost-to-follow-up resulted in an estimated sample size of 138 eyes. Rounding upwards, up to a total of 140 eyes assured that there are 125 evaluable eyes at the time point of stability. ### 1. Clinical Inclusion and Exclusion Criteria Enrollment in the clinical study entitled: 'The Safety and Effectiveness of the Nidek EC-5000 Excimer Laser System Using Customized Aspheric Treatment zone (CATz) Assisted LASIK for the Treatment of Myopic Astigmatism in Virgin Eyes with Corneal Irregularity' was limited to subjects who met the selection criteria listed in tables 1 and 2 below: | Inclusion | | --- | | 21 years of age or older | | Had an uncorrected refractive error that could be surgically treated by LASIK consisting of myopic astigmatism with a spherical component of -0.5 D to -7.0 D, and an astigmatic component of -0.50 D to -4.0 D, based on the manifest refraction in the operative study eye | | Target postoperative refraction of 0.00 D sphere and 0.00 D cylinder in the operative study eye | | BSCVA distance of 20/25 or better in each eye | | 0.75 D SE or less difference between the manifest or cycloplegic refractions and the OPD-Scan refraction used for the Final Fit™ treatment calculation | PMA P970053/S11 FDA Summary of Safety and Effectiveness Data Page 7 {7} | Inclusion | | --- | | 15 degrees or less difference between the axes of the manifest or cycloplegic refractions and the OPD-Scan refraction used for the Final Fit™ treatment calculation | | OPD-Scan image with a 5 mm or larger pupil diameter that was without artifacts and 10 microns or less of corneal irregularity | | A stable correction (± 0.5 D) in the operative study eye, as determined by MRSE for a minimum of 12-months prior to surgery | | For contact lens wearers, demonstration of a stable refraction (± 0.5 D MRSE) of the manifest refraction and topography on two consecutive exam dates at least 7 days apart after discontinuation of contact lens wear | | Normal topography | | Signed written informed consent | | Willingness and ability to comply with schedule for follow-up visits. | **Table 1: Inclusion Criteria** | Exclusion | | --- | | An acute or chronic disease or illness that would increase the operative risk or confound the outcome(s) of the study (e.g., severe dry eyes, immunocompromised, connective tissue disease with ocular involvement, clinically significant atopic disease, diabetes with ocular involvement, etc.) | | Use of systemic medications that may confound the outcome of the study or increase the risk to the subject, including, but not limited to steroids, antimetabolites, etc. | | Previous ocular condition (other than refractive error) that may predispose the eye for future complications, for example: history of corneal disease (e.g., herpes simplex, herpes zoster keratitis, recurrent erosion syndrome or corneal dystrophy, etc.) | | Evidence of retinal vascular disease | | Keratoconus or unstable central keratometry readings with irregular mires | | Glaucoma or glaucoma suspect by exam findings | | Previous intraocular or corneal surgery, except strabismus surgery | | Pregnancy or lactation during the course of the study | | A known sensitivity to study medications | | Mixed astigmatism in the operative study eye, based on the screening manifest refraction | | Surgical treatment plan in the study eye(s) for monovision or intentional undercorrection or overcorrection | | Residual corneal bed thickness remaining after laser ablation is calculated preoperatively to be less than 250 microns in the operative study eye | | Preoperative central corneal thickness of less than 475 microns in the operative study eye | | Concurrent participation in other ophthalmic clinical trials | | Contact lens intolerance in subjects who are not undergoing bilateral treatment | | Mesopic pupil size ≥ 8mm | **Table 2: Exclusion Criteria** PMA P970053/S11 FDA Summary of Safety and Effectiveness Data Page 8 {8} ## 2. Follow-Up Schedule Subjects completed follow-up examinations at 1 day, 1 week, and 1, 3, 6, 9, and 12-months post-LASIK. The objective parameters measured both preoperatively and postoperatively, along with their respective time schedule are detailed in Table 3, below: | Procedure | Screen | Surgery | POSTOPERATIVE VISITS | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 1 DAY | 1 WK | 1 MO | 3 MO | 6 MO | 9 MO | 12 MO | 18 MO | 24 MO | | Medical History | X | X | X | X | X | X | X | X | X | X | X | | Ocular History | X | X | X | X | X | X | X | X | X | X | X | | Medication History | X | X | X | X | X | X | X | X | X | X | X | | Demographics | X | | | | | | | | | | | | BCVA Distance | X | | | X | X | X | X | X | X | X | X | | BCVA Near | X | | | X | X | X | X | X | X | X | X | | UCVA Distance | X | | X | X | X | X | X | X | X | X | X | | UCVA Near | X | | | | | X | X | X | X | X | X | | Manifest Refraction | X | X | | X | X | X | X | X | X | X | X | | Cycloplegic Refraction | X | | | | | | X | X | X | X | X | | Intraocular Pressure Measurement | X | | | X | X | X | X | X | X | X | X | | Slit Lamp Exam | X | | X | X | X | X | X | X | X | X | X | | Pupil Size Measurement | X | | X^{7} | X^{7} | X^{7} | X^{7} | X | X | X | X | X | | Dilated Fundus Examination | X | | | | | | X | X | X | X | X | | Pachymetry, Keratometry | X | | | | | | X | X | X | X | X | | OPD-Scan Topography and Power Analysis | X | | | | X | X | X | X | X | X | X | | Contrast sensitivity | X | | | | | | X | | | | | | RSVP Questionnaire | X | | | | X | X | X | X | X | X | X | | Subjective Complaint Questionnaire | X | | | | X | X | X | X | X | X | X | | Sign Consent | X | | | | | | | | | | | | Complications | | X | X | X | X | X | X | X | X | X | X | | Adverse Events | | X | X | X | X | X | X | X | X | X | X | **Table 3: Follow-Up Schedule – Postoperative Visits** Subjects were permitted to have second eyes (fellow eyes) treated at the discretion of the investigator at the same time as the first eyes (primary eyes) or after the primary eye treatment. There was one (1) retreatment/ secondary surgical intervention. One subject experienced a small hemorrhage under the flap, a traumatic injury with diffuse lamellar keratitis (DLK), and a retreatment in the right eye (OD). This subject has a resultant BSCVA of 20/20, and has not suffered any significant loss of visual acuity compared to baseline. Subjects were ineligible for retreatment unless specific permission was obtained from the applicant, Food and Drug Administration (FDA), and the Institutional Review Board (IRB). PMA P970053/S11 FDA Summary of Safety and Effectiveness Data Page 9 {9} ### 3. Clinical Endpoints Safety and Effectiveness Criteria The primary safety endpoints were: 1) Percentage of eyes that had a loss of two or more lines in BSCVA 2) Percentage of eyes that had a BSCVA worse than 20/25 if the BSCVA was 20/20 or better preoperatively 3) Percentage of eyes that had a BSCVA worse than 20/40 These endpoints were measured postoperatively at 1, 3, 6, 9 and 12-months. Specifically, safety outcomes were assessed, at 3-months postoperatively, the time of refractive stability. Other safety endpoints included adverse events (AEs), complications, evaluation of corneal haze and intraocular pressure, symptoms/problems/complaints assessed in subject questionnaires and contrast sensitivity. Primary effectiveness endpoints that were evaluated over time include: 1) Refractive predictability 2) Uncorrected visual acuity 3) Refractive stability Other effectiveness endpoints include Zernike analysis of topography data and a patient symptom questionnaire that assesses vision related quality of life factors. These primary effectiveness endpoints were measured postoperatively at 1, 3, 6, 9 and 12-months. Specifically, effectiveness outcomes at 3-months postoperatively were assessed, as refractive stability is reached by that time. Table 4 indicates target criteria for primary safety and effectiveness outcomes: | Target Criteria for Primary Safety and Effectiveness Outcomes | | | | --- | --- | --- | | Criteria | Parameter | CATz-1 Myopic Astigmatism Target Criteria | | Effectiveness | Percentage of eyes with UCVA of 20/40 or better (BSCVA 20/20 or better preop) | 85% | | | Percentage of eyes achieving refractive predictability (attempted versus achieved) that are within: | | | | ±0.50D | 50% | | | ±1.00D | 75% | PMA P970053/S11 FDA Summary of Safety and Effectiveness Data Page 10 {10} | Safety | Percentage of eyes losing 2 or more lines of BSCVA | <5% | | --- | --- | --- | | | Percentage of eyes that have BSCVA worse than 20/25 if BSCVA 20/20 or better preoperatively | <1% | **Table 4:** Target Criteria for Primary Safety and Effectiveness Outcomes ### **B. Accountability of PMA Cohort** At the time of database lock, of the 136 eyes enrolled (135 eyes treated) in the CATz-1 PMA study, 94% (127/135) of treated eyes are available for analysis at the timepoint of refractive stability, the 3-month post-operative visit. Eighty-four percent (113/135) of treated eyes are available for analysis at the completion of the study, the 12-month post-operative visit. A total of 135 eyes in 74 subjects were treated between December 14, 2005 and September 28, 2006. Main statistical analyses to determine safety and efficacy included clinical data for the 135 eyes treated. Accountability for the 135 treated eye cohort is summarized below in Table 5 for all eyes treated. One enrolled eye was not treated due to a buttonhole created during the keratectomy. This eye did not undergo a primary LASIK treatment. | Accountability by Eye for All Treated Eyes | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | Status | Day 1 | Week 1 | Month 1 | Month 3 | Month 6 | Month 9 | Month 12 | | Enrolled [Treated] (N) | 135 | 135 | 135 | 135 | 135 | 135 | 135 | | Available for Analysis | 135 (100%) | 135 (100%) | 135 (100%) | 127 (94%) | 133 (99%) | 117 (87%) | 113 (84%) | | Discontinued | 0 | 0 | 0 | 0 | 0 | 0 | 2 (1%) | | Active (Not Eligible for Interval) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | Lost to Follow-up | 0 | 0 | 0 | 0 | 0 | 2 (1%) | 16 (12%) | | Missed Visit (Accounted for) | 0 | 0 | 0 | 8 (6%) | 2 (1%) | 16 (12%) | 4 (3%) | | Accountability | 100% | 100% | 100% | 94% | 99% | 87% | 85% | **Table 5:** Accountability by Eye for All Treated Eyes PMA P970053/S11 FDA Summary of Safety and Effectiveness Data Page 11 {11} ## C. Study Population Demographics and Baseline Parameters ### Demographics Table 6 presents demographic information at each site for the cohort of 74 subjects enrolled in the study. | | | Site 1 (N=18) | Site 2 (N=21) | Site 3 (N=16) | Site 4 (N=19) | Total (N=74) | p-value[1] | | --- | --- | --- | --- | --- | --- | --- | --- | | Gender | | | | | | | 0.759 | | | Male | 9 (50%) | 8 (38%) | 8 (50%) | 7 (37%) | 32 (43%) | | | | Female | 9 (50%) | 13 (62%) | 8 (50%) | 12 (63%) | 42 (57%) | | | Age | | | | | | | <.001 | | | n | 18 | 21 | 16 | 19 | 74 | | | | mean (SD) | 36.9 (7.1) | 39.5 (7.9) | 34.9 (9.5) | 28.7 (5.6) | 35.1 (8.5) | | | | median | 35.5 | 39.0 | 33.5 | 28.0 | 34.0 | | | | min,max | 23.0 , 50.0 | 23.0 , 55.0 | 23.0 , 64.0 | 21.0 , 41.0 | 21.0 , 64.0 | | | Race | | | | | | | <.001 | | | Caucasian | 18 (100%) | 12 (57%) | 12 (75%) | 0 (0%) | 42 (57%) | | | | Black | 0 (0%) | 0 (0%) | 3 (19%) | 0 (0%) | 3 (4%) | | | | Asian | 0 (0%) | 3 (14%) | 1 (6%) | 0 (0%) | 4 (5%) | | | | Hispanic | 0 (0%) | 5 (24%) | 0 (0%) | 19 (100%) | 24 (32%) | | | | Other | 0 (0%) | 1 (5%) | 0 (0%) | 0 (0%) | 1 (1%) | | | [1] Chi-square test for categorical variables and t-test for continuous variables | | | | | | | | **Table 6: demographic information** There was a statistically significant difference in the distribution of races across the sites (p<0.001). This difference in race was due to the high proportion of Hispanic patients enrolled at Site 7. Published literature evaluating racial differences have demonstrated there are no significant differences between the Hispanic and Caucasian populations for corneal curvature, central corneal thickness, refractive measurements, preoperative astigmatism, or intraocular pressure$^{1,2}$. Therefore, the outcomes would not be expected to be different between the two groups. Thus the predominance of Hispanic population should have no clinically significant effect on the outcomes that would affect poolability of the data. PMA P970053/S11 FDA Summary of Safety and Effectiveness Data Page 12 {12} ## **Baseline Refractive Parameters** The preoperative bin distribution is based on the preoperative manifest refraction, specifically sphere and cylinder. All eyes were treated for myopia with astigmatism with a target refraction of emmetropia. All eyes enrolled and treated had -0.50 D or more of cylinder in the study. Table 7, below, provides the bin distribution stratified by preoperative sphere and by preoperative cylinder. | **Bin Distribution for All Primary and Fellow Eyes** | | | | | --- | --- | --- | --- | | Sphere | Primary n (%) | Fellow n (%) | Total | | -1.00 to -2.00 D | 26 (19%) | 15 (11%) | 41 | | -2.01 to -3.00 D | 10 (7%) | 16 (12%) | 26 | | -3.01 to -4.00 D | 21 (16%) | 17 (13%) | 38 | | -4.01 to -5.00 D^{3} | 9 (7%) | 9 (7%) | 18 | | -5.01 to -6.00 D^{3} | 8 (6%) | 4 (3%) | 12 | | Total | 74 | 61 | 135 | | Cylinder | | | | | -0.50 to -0.75 D | 38 (28%) | 34 (25%) | 72 | | -0.76 to -1.00 D | 13 (10%) | 8 (6%) | 21 | | -1.01 to -2.00 D | 20 (15%) | 13 (10%) | 33 | | -2.01 to -3.00 D^{[1]} | 2 (1%) | 5 (4%) | 7 | | -3.01 to -4.00 D^{[2]} | 1 (1%) | 1 (1%) | 2 | | Total | 74 | 61 | 135 | | [1] Outside range of approved indication for use: Flag warning | | | | | [2] Outside range of approved indication for use: Locked out | | | | **Table 7:** Bin Distribution for All Primary and Fellow Eyes The range of refractive error treated in the CATz-1 study is listed in Table 8, below: | | Minimum | Maximum | | --- | --- | --- | | Sphere | -1.00 | -6.00 | | Cylinder | -0.5 | -3.5 | | MRSE | -1.25 | -6.88 | **Table 8:** The range of refractive error treated in the CATz-1 study PMA P970053/S11 FDA Summary of Safety and Effectiveness Data Page 13 {13} ## D. Safety and Effectiveness Results ### Safety Results The analysis of safety was based on the treated cohort of 136 study eyes available for analysis at the 3-month evaluation, the time point of refractive stability. The primary safety outcomes for this study and overall AEs are presented below Tables 10, 11 and 12. Given the device system did not raise any new safety issues in comparison to the previously approved system, it is appropriate to leverage the prior clinical data and experience from this device to require only 125 eyes to support approval; the minimum number of eyes needed to evaluate the primary effectiveness endpoint. | Comparison of LASIK Safety Criteria at 3 Months Post-LASIK (timepoint of stability) | | | | --- | --- | --- | | Parameter | CATz-1 Myopic Astigmatism Target Criteria | CATz-1 Myopic Astigmatism 3 Months Postop | | Percentage of eyes losing 2 or more lines of BSCVA | <5% | 2/123 (1.6%) | | Percentage of eyes that have BSCVA worse than 20/25 if BSCVA 20/20 or better preoperatively | <1% | 2/97 (2.1%)* | **Table 9: Comparison of LASIK Safety Criteria at 3 Months Post-LASIK (timepoint of stability)** Table 10 lists all AEs (Table 11 lists AEs in descending order of overall incidence), including AEs both related and unrelated to the topography-assisted LASIK treatment, observed during the CATz-1 clinical study in descending order of the overall incidence rate. Any and all observations of the clinical reviewer are included in the table below. There were no AEs that led to any device design modifications during the PMA clinical study. The most common AEs related to the topography-assisted LASIK treatment occurring in over 5% of study subjects overall reported at the 3-month visit are: dry eye, 13% (9/70); halo vision, 9% (6/70); glare, 7% (5/70); and punctate keratitis, 9% (6/70). At the 6-month visit, dry eye decreases to 8% (6/73); halo vision 73). At the 9-month visit, dry eye decreases to 6% (4/64); halo vision increases to 5% (3/64); glare increases to 3% decreases to 0% (0/73); glare decreases to 1% (1/73) and punctate keratitis decreases to 1% (1/ (2/64) and punctate keratitis decreases to 3% (2/64). At the 12-month visit, dry eye further decreases to 5% (3/63); halo vision decreases to 0% (0/63); glare decreases to 0% (0/63) and punctate keratitis remains at 3% (2/63). The table below lists AEs by severity for all treated subjects with at least 5% overall incidence rate. PMA P970053/S11 FDA Summary of Safety and Effectiveness Data Page 14 {14} | **Adverse Events by Severity for All Treated Subjects** | | | | | | | --- | --- | --- | --- | --- | --- | | **Preferred Terms with at Least 5% Overall Incidence Rate are Included** | | | | | | | Preferred Term | Severity | Mo 3 (N=70) | Mo 6 (N=73) | Mo 9 (N=64) | Mo 12 (N=63) | | Any AE | Mild | 23 (33%) | 11 (15%) | 11 (17%) | 12 (19%) | | | Moderate | 3 (4%) | 1 (1%) | 3 (5%) | 1 (2%) | | | Severe | 1 (1%) | 2 (3%) | 0 | 0 | | | Unknown | 0 | 1 (1%) | 0 | 2 (3%) | | Corneal deposits | Mild | 0 | 0 | 0 | 0 | | Corneal opacity | Mild | 2 (3%) | 1 (1%) | 1 (2%) | 0 | | Corneal striae | Mild | 1 (1%) | 0 | 0 | 0 | | | Moderate | 0 | 0 | 0 | 0 | | Diplopia | Mild | 0 | 0 | 1 (2%) | 0 | | | Moderate | 0 | 0 | 0 | 0 | | | Severe | 0 | 0 | 0 | 0 | | Dry eye | Mild | 8 (11%) | 5 (7%) | 4 (6%) | 3 (5%) | | | Moderate | 2 (3%) | 0 | 1 (2%) | 0 | | | Severe | 0 | 1 (1%) | 0 | 0 | | Eye pain | Mild | 0 | 0 | 2 (3%) | 0 | | | Moderate | 0 | 0 | 0 | 0 | | Foreign body sensation in eyes | Mild | 0 | 0 | 1 (2%) | 0 | | | Moderate | 0 | 0 | 0 | 0 | | Glare | Mild | 4 (6%) | 0 | 2 (3%) | 0 | | | Moderate | 1 (1%) | 0 | 0 | 0 | | | Severe | 0 | 1 (1%) | 0 | 0 | | Halo vision | Mild | 4 (6%) | 0 | 2 (3%) | 0 | | | Moderate | 1 (1%) | 0 | 1 (2%) | 0 | | | Severe | 1 (1%) | 0 | 0 | 0 | | Headache | Mild | 1 (1%) | 0 | 1 (2%) | 0 | | Meibomian gland discharge | Mild | 0 | 0 | 0 | 1 (2%) | | Photophobia | Mild | 0 | 1 (1%) | 0 | 2 (3%) | | | Moderate | 0 | 0 | 0 | 0 | | | Severe | 1 (1%) | 0 | 0 | 0 | | Photopsia^{[1]} | Mild | 1 (1%) | 1 (1%) | 1 (2%) | 2 (3%) | | | Severe | 0 | 0 | 0 | 0 | | Punctate keratitis | Mild | 6 (9%) | 1 (1%) | 2 (3%) | 2 (3%) | | Vision blurred | Mild | 2 (3%) | 0 | 0 | 1 (2%) | | Visual acuity reduced transiently | Mild | 1 (1%) | 0 | 0 | 0 | [1] Photopsia denotes 'starbursts' PMA P970053/S11 FDA Summary of Safety and Effectiveness Data Page 15 {15} | Adverse Events in Descending Order of Overall Incidence for All Treated Patients | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Preferred Term | Intraop (N=74) | Day 1 (N=74) | Wk 1 (N=74) | Mo 1 (N=74) | Mo 3 (N=70) | Mo 6 (N=73) | Mo 9 (N=64) | Mo 12 (N=63) | Mo 18 (N=15) | Mo 24 (N=6) | Overall (N=74) | | Any AE | 3 (4%) | 20 (27%) | 34 (46%) | 27 (36%) | 27 (39%) | 15 (21%) | 14 (22%) | 15 (24%) | 7 (47%) | 1 (17%) | 59 (80%) | | Dry eye | 0 | 1 (1%) | 5 (7%) | 10 (14%) | 10 (14%) | 6 (8%) | 5 (8%) | 3 (5%) | 3 (20%) | 0 | 36 (49%) | | Halo vision | 0 | 6 (8%) | 9 (12%) | 8 (11%) | 6 (9%) | 0 | 3 (5%) | 0 | 0 | 0 | 19 (26%) | | Glare | 0 | 5 (7%) | 7 (9%) | 5 (7%) | 5 (7%) | 1 (1%) | 2 (3%) | 0 | 0 | 0 | 15 (20%) | | Corneal striae | 1 (1%) | 3 (4%) | 5 (7%) | 3 (4%) | 1 (1%) | 0 | 0 | 0 | 0 | 0 | 12 (16%) | | Punctate keratitis | 0 | 4 (5%) | 3 (4%) | 2 (3%) | 6 (9%) | 1 (1%) | 2 (3%) | 2 (3%) | 2 (13%) | 0 | 12 (16%) | | Photopsia^{[1]} | 1 (1%) | 0 | 5 (7%) | 0 | 1 (1%) | 1 (1%) | 1 (2%) | 2 (3%) | 0 | 0 | 10 (14%) | | Foreign body sensation in eyes | 0 | 2 (3%) | 3 (4%) | 4 (5%) | 0 | 0 | 1 (2%) | 0 | 0 | 0 | 9 (12%) | | Corneal opacity | 0 | 3 (4%) | 1 (1%) | 1 (1%) | 2 (3%) | 1 (1%) | 1 (2%) | 0 | 0 | 0 | 8 (11%) | | Vision blurred | 0 | 2 (3%) | 3 (4%) | 0 | 2 (3%) | 0 | 0 | 1 (2%) | 0 | 1 (17%) | 8 (11%) | | Eye pain | 0 | 0 | 2 (3%) | 3 (4%) | 0 | 0 | 2 (3%) | 0 | 1 (7%) | 0 | 7 (9%) | | Visual acuity reduced transiently | 0 | 2 (3%) | 2 (3%) | 1 (1%) | 1 (1%) | 0 | 0 | 0 | 1 (7%) | 0 | 6 (8%) | | Meibomian gland discharge | 0 | 1 (1%) | 3 (4%) | 0 | 0 | 0 | 0 | 1 (2%) | 0 | 0 | 5 (7%) | | Corneal deposits | 0 | 1 (1%) | 3 (4%) | 1 (1%) | 0 | 0 | 0 | 0 | 0 | 0 | 4 (5%) | | Diplopia | 0 | 0 | 3 (4%) | 1 (1%) | 0 | 0 | 1 (2%) | 0 | 1 (7%) | 0 | 4 (5%) | | Headache | 0 | 0 | 1 (1%) | 1 (1%) | 1 (1%) | 0 | 1 (2%) | 0 | 0 | 0 | 4 (5%) | | Photophobia | 0 | 1 (1%) | 1 (1%) | 2 (3%) | 1 (1%) | 1 (1%) | 0 | 2 (3%) | 0 | 0 | 4 (5%) | | Keratitis | 0 | 2 (3%) | 0 | 1 (1%) | 0 | 0 | 0 | 0 | 0 | 0 | 3 (4%) | | Visual acuity reduced | 0 | 0 | 0 | 0 | 0 | 1 (1%) | 1 (2%) | 0 | 1 (7%) | 0 | 3 (4%) | | Asthenopia | 0 | 0 | 1 (1%) | 0 | 1 (1%) | 0 | 0 | 0 | 0 | 0 | 2 (3%) | | Blepharospasm | 0 | 0 | 0 | 1 (1%) | 1 (1%) | 0 | 0 | 0 | 0 | 0 | 2 (3%) | | Conjunctival haemorrhage | 0 | 1 (1%) | 1 (1%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 (3%) | | Hypersensitivity | 0 | 0 | 0 | 1 (1%) | 0 | 1 (1%) | 0 | 0 | 0 | 0 | 2 (3%) | | Loss of visual contrast sensitivity | 0 | 1 (1%) | 1 (1%) | 1 (1%) | 1 (1%) | 1 (1%) | 1 (2%) | 0 | 0 | 0 | 2 (3%) | PMA P970053/S11 FDA Summary of Safety and Effectiveness Data Page 16 {16} | Meibomian gland dysfunction | 0 | 1 (1%) | 0 | 0 | 0 | 0 | 1 (2%) | 0 | 0 | 0 | 2 (3%) | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Vitreous floaters | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (2%) | 1 (7%) | 0 | 2 (3%) | | Allergy to animal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (2%) | 0 | 0 | 1 (1%) | | Astigmatism | 0 | 0 | 0 | 0 | 0 | 1 (1%) | 0 | 0 | 0 | 0 | 1 (1%) | | Cardiac disorder | 0 | 0 | 1 (1%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (1%) | | Chalazion | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (2%) | 0 | 0 | 1 (1%) | | Conjunctivitis viral | 0 | 1 (1%) | 1 (1%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (1%) | | Corneal abrasion | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (7%) | 0 | 1 (1%) | | Corneal epithelium defect | 0 | 0 | 0 | 1 (1%) | 0 | 0 | 0 | 0 | 0 | 0 | 1 (1%) | | Corneal infiltrates | 0 | 0 | 0 | 1 (1%) | 0 | 0 | 0 | 0 | 0 | 0 | 1 (1%) | | Corneal scar | 0 | 1 (1%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (1%) | | Depression | 0 | 0 | 0 | 0 | 0 | 1 (1%) | 0 | 0 | 0 | 0 | 1 (1%) | | Dizziness | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (2%) | 0 | 0 | 1 (1%) | | Eye injury | 0 | 0 | 0 | 1 (1%) | 0 | 0 | 0 | 0 | 0 | 0 | 1 (1%) | | Eye irritation | 0 | 0 | 0 | 0 | 1 (1%) | 0 | 0 | 0 | 0 | 0 | 1 (1%) | | Eye laser scar | 0 | 0 | 0 | 1 (1%) | 0 | 0 | 0 | 0 | 0 | 0 | 1 (1%) | | Eye pruritus | 0 | 0 | 0 | 0 | 1 (1%) | 0 | 0 | 0 | 0 | 0 | 1 (1%) | | Facial palsy | 0 | 0 | 0 | 1 (1%) | 0 | 0 | 0 | 0 | 0 | 0 | 1 (1%) | | Hepatitis | 0 | 0 | 0 | 0 | 0 | 1 (1%) | 0 | 0 | 0 | 0 | 1 (1%) | | Hypermetropia | 0 | 0 | 0 | 1 (1%) | 0 | 0 | 0 | 0 | 0 | 0 | 1 (1%) | | Hypothyroidism | 0 | 0 | 1 (1%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (1%) | | Injury corneal | 1 (1%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (1%) | | Intraocular pressure increased | 0 | 0 | 1 (1%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (1%) | | Migraine | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (2%) | 0 | 0 | 1 (1%) | | Migraine with aura | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (7%) | 0 | 1 (1%) | | Nasopharyngitis | 0 | 0 | 0 | 0 | 1 (1%) | 0 | 0 | 0 | 0 | 0 | 1 (1%) | | Ocular hyperaemia | 0 | 0 | 1 (1%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (1%) | | Pain | 0 | 0 | 0 | 0 | 1 (1%) | 0 | 0 | 0 | 0 | 0 | 1 (1%) | | Pregnancy | 0 | 0 | 0 | 0 | 0 | 1 (1%) | 0 | 0 | 0 | 0 | 1 (1%) | | Presbyopia | 0 | 0 | 0 | 0 | 1 (1%) | 0 | 0 | 0 | 0 | 0 | 1 (1%) | | Pruritus allergic | 0 | 0 | 0 | 1 (1%) | 0 | 0 | 0 | 0 | 0 | 0 | 1 (1%) | PMA P970053/S11 FDA Summary of Safety and Effectiveness Data Page 17 {17} | Retinal pigment epitheliopathy | 0 | 0 | 0 | 0 | 0 | 1 (1%) | 0 | 0 | 0 | 0 | 1 (1%) | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Rib fracture | 0 | 0 | 0 | 0 | 0 | 0 | 1 (2%) | 0 | 0 | 0 | 1 (1%) | | Seasonal allergy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (2%) | 0 | 0 | 1 (1%) | | Syncope | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (2%) | 0 | 0 | 1 (1%) | | Upper limb fracture | 0 | 0 | 0 | 0 | 0 | 1 (1%) | 0 | 0 | 0 | 0 | 1 (1%) | | Urticaria | 1 (1%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (1%) | [1] Photopsia denotes “starbursts” Table 11: Adverse Events in Descending Order of Overall Incidence for All Treated Patients ### **Corneal Haze** Corneal haze was graded at each postoperative time point after observation on the slit lamp examination. Rare occurrences of haze were reported in the CATz-1 clinical trial, with only single reports of transient trace haze at the 1 and 3-month visits. Topography-assisted LASIK for the treatment of myopic astigmatism with the EC-5000 Excimer Laser does not induce corneal haze postoperatively. ### **Intraocular Pressure** Intraocular pressure was measured by Goldmann applanation tonometry at the slit lamp. There were no clinically significant changes (defined as > 10mmHg increase) between the intraocular pressure measurements obtained preoperatively and postoperatively. ### **Serious Adverse Events** There was one reported serious adverse event of corneal striae reported in the CATz-1 clinical study. Table 12 indicates the one serious adverse event reported. | Serious Adverse Events for All Treated Eyes | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Page No. | AE No. | Description | Preferred Term | Visit | Start Date | End Date | SAE^{A} | Sev^{B} | Rel^{C} | Act^{D} | Out^{E} | | 100.00 | 1 | OS flap striae | Corneal striae | Surg | 04/12/2006 | 04/13/2006 | 1 | 2 | 5 | 4 | 1 | | A=Yes, 2=No | | | | | | | | | | | | | B Severity: 1=Mild, 2=Moderate, 3=Severe | | | | | | | | | | | | | C Relationship: 1=None, 2=Unlikely, 3=Possible, 4=Probable, 5=Definite | | | | | | | | | | | | | D Action: 1=None, 2=Concomitant Medication, 3=Discontinued, 4=Other | | | | | | | | | | | | | E Outcome: 1=Resolved, 2=Not Resolved, 3=Death | | | | | | | | | | | | Table 12: Serious Adverse Events for All Treated Eyes The subject that experienced the serious adverse event was a 32 year old female subject (age at the time of CATz-1 screening) who underwent uneventful bilateral CATz-1 LASIK surgery for the treatment of myopic astigmatism. The postoperative course for the right eye is unremarkable. At the 1-day postop visit, the UCVA OS was 20/25 and striae were PMA P970053/S11 FDA Summary of Safety and Effectiveness Data Page 18 {18} observed at the slit lamp exam. The corneal flap was re-floated at the 1-day postop visit to remove the striae. The striae were no longer present at the 1-week slit lamp. At the 1-month visit, the subject reports fluctuation of vision on the patient subjective questionnaire. This was the only visit the fluctuation of vision was reported. ## Complications As summarized in table 13, the most commonly occurring postoperative complication at month-3, or later, was dry eye requiring chronic artificial tears or punctual plugs. Other (Surg) refers to two corneal flap refloats and one retreatment. | Complications for All Treated Subjects | | | | | | --- | --- | --- | --- | --- | | Complication | Mo 3 (N=70) | Mo 6 (N=73) | Mo 9 (N=64) | Mo 12 (N=63) | | Any Complications | 15 (21%) | 11 (15%) | 4 (6%) | 7 (11%) | | Diffuse Lamellar Keratitis | 0 | 0 | 0 | 0 | | Dry Eye Requiring Chronic Artificial Tears or Punctal Plugs | 4 (6%) | 3 (4%) | 2 (3%) | 2 (3%) | | Foreign Body Sensation | 0 | 0 | 0 | 0 | | Ghosts or Double Images | 0 | 0 | 0 | 0 | | Loss of 2 lines BCVA | 1 (1%) | 0 | 0 | 0 | | Misaligned Flap | 0 | 0 | 0 | 0 | | Miscreated Flap | 0 | 0 | 0 | 0 | | Other (AE) | 11 (16%) | 8 (11%) | 2 (3%) | 5 (8%) | | Other (Surg) | 0 | 0 | 0 | 0 | | Pain | 0 | 0 | 1 (2%) | 1 (2%) | **Table 13:** Complications for All Treated Subjects ## Patient Questionnaire Subjective visual complaints were obtained from each subject using a self-administered 10-point questionnaire to record symptoms. Subjects were asked to rate the presence or absence of each visual complaint in their CATz-treated eye(s) at baseline before the CATz topography-assisted LASIK treatment and each postoperative visit, beginning at 1-month. Subjects were instructed to rate the absence of a complaint as 'none,' and the presence of a complaint was rated as 'mild,' 'moderate,' 'marked' or 'severe.' Values stated as 'Unknown' refer to questions where the subject did not provide an answer. Subjective visual complaints noted on the patient questionnaire were noted as either AEs or complications at the discretion of the clinical investigator. The results of the subjective questionnaire at baseline and at each postoperative examination are summarized by symptom in table 14. PMA P970053/S11 FDA Summary of Safety and Effectiveness Data Page 19 {19} | Subject Symptoms Recorded via Self-Administered Symptom Questionnaire for All Treated Eyes | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Question | Response | Screening (N=135) | Mo 1 (N=135) | Mo 3 (N=127) | Mo 6 (N=133) | Mo 9 (N=117) | Mo 12 (N=113) | Mo 18 (N=24) | Mo 24 (N=10) | | Light Sensitivity | None | 93 (69%) | 88 (65%) | 95 (75%) | 105 (79%) | 94 (80%) | 81 (72%) | 14 (58%) | 3 (30%) | | | Mild | 20 (15%) | 28 (21%) | 24 (19%) | 21 (16%) | 17 (15%) | 23 (20%) | 3 (13%) | 2 (20%) | | | Moderate | 7 (5%) | 18 (13%) | 4 (3%) | 7 (5%) | 5 (4%) | 5 (4%) | 2 (8%) | 0 | | | Marked | 4 (3%) | 0 | 2 (2%) | 0 | 1 (1%) | 0 | 1 (4%) | 0 | | | Severe | 2 (1%) | 1 (1%) | 0 | 0 | 0 | 0 | 0 | 0 | | | Unknown | 9 (7%) | 0 | 2 (2%) | 0 | 0 | 4 (4%) | 4 (17%) | 5 (50%) | | Difficulty Driving at Night | None | 63 (47%) | 111 (82%) | 110 (87%) | 117 (88%) | 103 (88%) | 93 (82%) | 14 (58%) | 3 (30%) | | | Mild | 15 (11%) | 20 (15%) | 13 (10%) | 15 (11%) | 14 (12%) | 14 (12%) | 4 (17%) | 1 (10%) | | | Moderate | 18 (13%) | 2 (1%) | 2 (2%) | 1 (1%) | 0 | 2 (2%) | 2 (8%) | 1 (10%) | | | Marked | 21 (16%) | 2 (1%) | 0 | 0 | 0 | 0 | 0 | 0 | | | Severe | 9 (7%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | Unknown | 9 (7%) | 0 | 2 (2%) | 0 | 0 | 4 (4%) | 4 (17%) | 5 (50%) | | Reading Difficulty | None | 112 (83%) | 113 (84%) | 98 (77%) | 110 (83%) | 102 (87%) | 91 (81%) | 13 (54%) | 1 (10%) | | | Mild | 9 (7%) | 16 (12%) | 18 (14%) | 15 (11%) | 9 (8%) | 13 (12%) | 4 (17%) | 2 (20%) | | | Moderate | 5 (4%) | 3 (2%) | 6 (5%) | 6 (5%) | 3 (3%) | 4 (4%) | 1 (4%) | 0 | | | Marked | 0 | 1 (1%) | 2 (2%) | 2 (2%) | 3 (3%) | 1 (1%) | 2 (8%) | 2 (20%) | | | Severe | 0 | 2 (1%) | 1 (1%) | 0 | 0 | 0 | 0 | 0 | | | Unknown | 9 (7%) | 0 | 2 (2%) | 0 | 0 | 4 (4%) | 4 (17%) | 5 (50%) | | Double Vision | None | 124 (92%) | 124 (92%) | 120 (94%) | 130 (98%) | 114 (97%) | 108 (96%) | 16 (67%) | 3 (30%) | | | Mild | 2 (1%) | 8 (6%) | 3 (2%) | 2 (2%) | 3 (3%) | 1 (1%) | 2 (8%) | 1 (10%) | | | Moderate | 0 | 3 (2%) | 2 (2%) | 0 | 0 | 0 | 0 | 0 | | | Marked | 0 | 0 | 0 | 1 (1%) | 0 | 0 | 1 (4%) | 1 (10%) | | | Severe | 0 | 0 | 0 | 0 | 0 | 0 | 1 (4%) | 0 | | | Unknown | 9 (7%) | 0 | 2 (2%) | 0 | 0 | 4 (4%) | 4 (17%) | 5 (50%) | | Fluctuation in Vision | None | 106 (79%) | 93 (69%) | 98 (77%) | 99 (74%) | 94 (80%) | 91 (81%) | 16 (67%) | 1 (10%) | | | Mild | 14 (10%) | 37 (27%) | 22 (17%) | 31 (23%) | 22 (19%) | 16 (14%) | 2 (8%) | 2 (20%) | | | Moderate | 6 (4%) | 5 (4%) | 5 (4%) | 2 (2%) | 0 | 2 (2%) | 2 (8%) | 1 (10%) | | | Marked | 0 | 0 | 0 | 1 (1%) | 0 | 0 | 0 | 1 (10%) | | | Unknown | 9 (7%) | 0 | 2 (2%) | 0 | 1 (1%) | 4 (4%) | 4 (17%) | 5 (50%) | | Glare | None | 108 (80%) | 95 (70%) | 94 (74%) | 111 (83%) | 98 (84%) | 94 (83%) | 16 (67%) | 3 (30%) | | | Mild | 13 (10%) | 34 (25%) | 24 (19%) | 16 (12%) | 13 (11%) | 15 (13%) | 4 (17%) | 1 (10%) | | | Moderate | 2 (1%) | 6 (4%) | 7 (6%) | 6 (5%) | 6 (5%) | 0 | 0 | 1 (10%) | | | Marked | 3 (2%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | Unknown | 9 (7%) | 0 | 2 (2%) | 0 | 0 | 4 (4%) | 4 (17%) | 5 (50%) | | Halos | None | 111 (82%) | 96 (71%) | 88 (69%) | 105 (79%) | 94 (80%) | 89 (79%) | 16 (67%) | 3 (30%) | | | Mild | 12 (9%) | 33 (24%) | 32 (25%) | 28 (21%) | 19 (16%) | 20 (18%) | 4 (17%) | 2 (20%) | | | Moderate | 3 (2%) | 6 (4%) | 3 (2%) | 0 | 2 (2%) | 0 | 0 | 0 | PMA P970053/S11 FDA Summary of Safety and Effectiveness Data Page 20 {20} | Subject Symptoms Recorded via Self-Administered Symptom Questionnaire for All Treated Eyes | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Question | Response | Screening (N=135) | Mo 1 (N=135) | Mo 3 (N=127) | Mo 6 (N=133) | Mo 9 (N=117) | Mo 12 (N=113) | Mo 18 (N=24) | Mo 24 (N=10) | | | Marked | 0 | 0 | 2 (2%) | 0 | 2 (2%) | 0 | 0 | 0 | | | Unknown | 9 (7%) | 0 | 2 (2%) | 0 | 0 | 4 (4%) | 4 (17%) | 5 (50%) | | Starbursts | None | 112 (83%) | 98 (73%) | 95 (75%) | 106 (80%) | 101 (86%) | 84 (74%) | 16 (67%) | 3 (30%) | | | Mild | 11 (8%) | 27 (20%) | 24 (19%) | 27 (20%) | 12 (10%) | 23 (20%) | 4 (17%) | 0 | | | Moderate | 2 (1%) | 8 (6%) | 4 (3%) | 0 | 4 (3%) | 2 (2%) | 0 | 2 (20%) | | | Marked | 1 (1%) | 2 (1%) | 2 (2%) | 0 | 0 | 0 | 0 | 0 | | | Unknown | 9 (7%) | 0 | 2 (2%) | 0 | 0 | 4 (4%) | 4 (17%) | 5 (50%) | | Dryness | None | 94 (70%) | 56 (41%) | 48 (38%) | 68 (51%) | 62 (53%) | 57 (50%) | 12 (50%) | 1 (10%) | | | Mild | 29 (21%) | 57 (42%) | 45 (35%) | 44 (33%) | 40 (34%) | 43 (38%) | 7 (29%) | 2 (20%) | | | Moderate | 3 (2%) | 14 (10%) | 28 (22%) | 20 (15%) | 14 (12%) | 7 (6%) | 1 (4%) | 2 (20%) | | | Marked | 0 | 2 (1%) | 2 (2%) | 1 (1%) | 1 (1%) | 2 (2%) | 0 | 0 | | | Severe | 0 | 6 (4%) | 2 (2%) | 0 | 0 | 0 | 0 | 0 | | | Unknown | 9 (7%) | 0 | 2 (2%) | 0 | 0 | 4 (4%) | 4 (17%) | 5 (50%) | | Pain | None | 119 (88%) | 119 (88%) | 117 (92%) | 127 (95%) | 113 (97%) | 106 (94%) | 17 (71%) | 4 (40%) | | | Mild | 6 (4%) | 12 (9%) | 8 (6%) | 5 (4%) | 4 (3%) | 3 (3%) | 3 (13%) | 1 (10%) | | | Moderate | 0 | 4 (3%) | 0 | 1 (1%) | 0 | 0 | 0 | 0 | | | Unknown | 10 (7%) | 0 | 2 (2%) | 0 | 0 | 4 (4%) | 4 (17%) | 5 (50%) | | Foreign Body Sensation | None | 111 (82%) | 95 (70%) | 105 (83%) | 116 (87%) | 103 (88%) | 95 (84%) | 17 (71%) | 4 (40%) | | | Mild | 15 (11%) | 34 (25%) | 16 (13%) | 15 (11%) | 14 (12%) | 14 (12%) | 3 (13%) | 1 (10%) | | | Moderate | 0 | 6 (4%) | 2 (2%) | 1 (1%) | 0 | 0 | 0 | 0 | | | Severe | 0 | 0 | 0 | 1 (1%) | 0 | 0 | 0 | 0 | | | Unknown | 9 (7%) | 0 | 4 (3%) | 0 | 0 | 4 (4%) | 4 (17%) | 5 (50%) | | Other | None | 35 (26%) | 37 (27%) | 30 (24%) | 37 (28%) | 29 (25%) | 35 (31%) | 10 (42%) | 5 (50%) | | | Mild | 0 | 2 (1%) | 2 (2%) | 0 | 0 | 0 | 0 | 0 | | | Moderate | 2 (1%) | 0 | 0 | 0 | 2 (2%) | 0 | 0 | 0 | | | Marked | 2 (1%) | 0 | 1 (1%) | 0 | 0 | 1 (1%) | 0 | 0 | | | Unknown | 96 (71%) | 96 (71%) | 94 (74%) | 96 (72%) | 86 (74%) | 77 (68%) | 14 (58%) | 5 (50%) | **Table 14:** Subject Symptoms Recorded via Self-Administered Symptom Questionnaire for All Treated Eyes Visual symptoms after topography-assisted LASIK were generally mild in severity. Eye dryness was the most commonly reported subject complaint that occurred in the early 1 or 3-month postoperative period, with 4% of the eyes (6/135) reporting severe dry eye at 1-month and 2% (2/127) reporting severe dry eye at the 3-month visit. This is not an atypical finding after LASIK surgery. The single report of severe light sensitivity at 1-month postoperatively also reported severe light sensitivity at screening. Light sensitivity improved to “marked” at 3-months, “moderate” at 6-months and was “marked” at 9-months. This subject had the fellow eye PMA P970053/S11 FDA Summary of Safety and Effectiveness Data Page 21 {21} treated with an alternative laser and reported the same severity of light sensitivity before and after LASIK treatment in both eyes. Reports of “marked” or “severe” reading difficulty are all in middle-aged presbyopic subjects who require reading glasses for their presbyopia and this finding is not unexpected for the age of these patients. The mean age for the 30 study subjects reporting any type of reading difficulty postoperatively was 40.3 years. Reports of “marked” double vision and fluctuation in one study eye accompanied a report of dry eye and are considered to be related to the subject’s eye dryness. One study subject reported “marked” double vision OD and “severe” double vision OS in the patient subjective questionnaire at the 18-month visit. At the 18-month visit, this study subject reported UCVA was 20/40 OU and manifest refraction was +0.25 sphere OD, +0.50 +0.25 x 140 OS. This subject reported a BCVA of 20/20 OU at the 18-month visit. A single report of severe foreign body sensation occurred at 6-months was completely resolved at the 9-month visit. One study subject reported “marked” starbursts at the 1-month and 3-month postoperative visits OU. Starbursts completely resolved at all further visits through the 12-month visit. Changes in the degree of severity of patient symptoms reported via the self-administered questionnaire at 3-months compared to baseline are summarized in Table 15. | Change in Degree of Severity of Subject Symptoms at 3 Months After Topography-Assisted LASIK Compared to Before LASIK for All Treated Eyes (N=116) | | | | | | --- | --- | --- | --- | --- | | Question | Preop Marked-Severe n (%) | Month 3 Marked-Severe n (%) | Percent Difference | p-value^{[1]} | | Difficulty Driving at Night | 25 (21.6%) | 0 | -21.6% | <.001 | | Double Vision | 0 | 0 | 0.0% | * | | Dryness | 0 | 4 (3.4%) | 3.4% | 0.125 | | Fluctuation in Vision | 0 | 0 | 0.0% | * | | Foreign Body Sensation | 0 | 0 | 0.0% | * | | Glare | 3 (2.6%) | 0 | -2.6% | 0.250 | | Halos | 0 | 0 | 0.0% | * | | Light Sensitivity | 6 (5.2%) | 2 (1.7%) | -3.4% | 0.219 | | Other | 0 | 1 (3.0%) | 3.0% | 1.000 | | Pain | 0 | 0 | 0.0% | * | | Reading Difficulty | 0 | 3 (2.6%) | 2.6% | 0.250 | | Starbursts | 1 (0.009%) | 0 | -0.009% | 1.000 | [1] McNemar's test. * indicates that the p-value cannot be calculated. Table 15: Change in Degree of Severity of Subject Symptoms at 3 Months post-LASIK Compared to Before LASIK for All Treated Eyes (N=116) {22} The greatest change is the improvement in night driving which showed about a 21.6% decrease in the number of eyes that had “marked” or “severe” difficulty driving at night after the CATz topography-assisted LASIK procedure compared to baseline. The improvement in difficulty with night driving was clinically significant, defined as a change of ±10% or more in the proportion of eyes reporting symptoms that were moderate to severe postoperatively compared to baseline. ### **Contrast Sensitivity** Contrast sensitivity was evaluated preoperatively and at 6-months after the topography-assisted LASIK procedure with and without glare under mesopic (3cd/m²) and photopic (85cd/m²) chart luminance conditions. Testing was performed using the StereoOptical Optec® 6500 Vision Tester and the Functional Acuity Contrast test (FACT™) Chart with Sine Wave Grating Chart, which tests at five spatial frequencies (1.5, 3, 6, 12 and 18 cycles/degree) and nine levels of contrast, that increase in contrast in equal 0.15 log units from Column 1 through Column 9 for each spatial frequency. The Optec® 6500 is calibrated by the manufacturer to provide photopic and mesopic test conditions and has a built-in glare source that is preset to deliver 10 lux glare luminance under photopic test conditions and 1 lux glare luminance under mesopic conditions. To perform the test, the subject reports the orientation of the grating (right, up or left). The test is scored by assigning the corresponding percentage contrast value for the target to the last correct grating (target) seen for each spatial frequency. The change in contrast sensitivity is then determined by calculating the difference between the contrast percentage at baseline and 6-months after the topography assisted LASIK for each spatial frequency. For the CATz-1 study, study eyes were tested at each of the five spatial frequencies using the manufacturer’s preset glare under the following test conditions: - Photopic (85 cd/m²) without glare - Photopic (85 cd/m²) with glare (10 lux) - Mesopic (3 cd/m²) without glare - Mesopic (3 cd/m²) with glare (1 lux) | Clinically Significant Change in Contrast Sensitivity for All Treated Eyes Tested Monocularly With Data at Pre-op and Post-op Month 6 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | Luminance | Glare | N | Clinically Significant Decrease | | Clinically Significant Increase | | | | | | n | % | n | % | | Mesopic | Yes | 69 | 5 | 7.2 | 14 | 20.3 | | | No | 104 | 4 | 3.8 | 11 | 10.6 | | Photopic | Yes | 69 | 2 | 2.9 | 15 | 21.7 | | | No | 104 | 7 | 6.7 | 10 | 9.6 | **Table 16: Clinically Significant Change in Contrast Sensitivity for All Treated Eyes** PMA P970053/S11 FDA Summary of Safety and Effectiveness Data Page 23 {23} The changes in logarithmic contrast sensitivity, based on the last correct grating seen for each spatial frequency reveal that there is a gain in photopic mean contrast sensitivity, both with and without glare, at most spatial frequencies tested. Spatial frequencies that show a mean loss in photopic contrast sensitivity, (1.5-cpd, 6-cpd (without glare), and 12 cpd (without glare)) are not statistically significant. Eyes treated with the CATz-1 topography-assisted LASIK procedure also showed a gain in mesopic mean contrast sensitivity with and without glare at all but the highest spatial frequencies of 12-cpd without glare and 18-cpd with and without glare at 6-months after the treatment. Clinically significant changes in contrast sensitivity are defined as a greater than 0.3 log unit increase (gain) or decrease (loss) at two or more spatial frequencies. Table 16 summarizes clinically significant changes in contrast sensitivity. ## Effectiveness Results The effectiveness analyses were based on 127 eyes that were available for analysis 3 months postoperatively. A comparison of the primary effectiveness parameters 3 months postoperatively (the time point for refractive stability) for the eyes treated in the cohort with the target effectiveness criteria from the CATz-1 Protocol is provided in Table 17. The outcomes exceed the target criteria for each effectiveness parameter specified in the protocol and combined with the safety profile, serve as the basis of approval. | Comparison of LASIK Effectiveness Criteria at 3 Months Post-LASIK (timepoint of stability) | | | | --- | --- | --- | | Parameter | CATz-1 Myopic Astigmatism Target Criteria | CATz-1 Myopic Astigmatism 3 Months Postop | | Percentage of eyes with UCVA of 20/40 or better | 85% | 127/127 (100.0%) | | Percentage of eyes achieving refractive predictability (attempted versus achieved) that are within: | | | | ±0.50D | 50% | 118/127 (92.9%) | | ±1.00D | 75% | 127/127 (100.0%) | | ±2.00D | NA | 127/127 (100.0%) | Table 17: Comparison of LASIK Effectiveness Criteria at 3 Months Post-LASIK PMA P970053/S11 FDA Summary of Safety and Effectiveness Data Page 24 {24} A summary of primary effectiveness variables is provided in Table 18 for the eyes treated in this myopia with astigmatism cohort. | Primary Effectiveness Variables for All Treated Eyes | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Effectiveness Variables | Statistic | Week 1 | Month 1 | Month 3 | Month 6 | Month 9 | Month 12 | Month 18 | Month 24 | | MRSE +/- 0.50 D | n/N | 117/133 | 126/135 | 118/127 | 113/124 | 108/117 | 94/109 | 18/21 | 5/7 | | | % | 88.0% | 93.3% | 92.9% | 91.1% | 92.3% | 86.2% | 85.7% | 71.4% | | | CI^{[1]} | (81.2, 93.0)% | (87.7, 96.9)% | (87.0, 96.7)% | (84.7, 95.5)% | (85.9, 96.4)% | (78.3, 92.1)% | (63.7, 97.0)% | (29.0, 96.3)% | | MRSE +/- 1.00 D | n/N | 132/133 | 135/135 | 127/127 | 123/124 | 116/117 | 109/109 | 21/21 | 7/7 | | | % | 99.2% | 100.0% | 100.0% | 99.2% | 99.1% | 100.0% | 100.0% | 100.0% | | | CI^{[1]} | (95.9, 100.0)% | (97.3, 100.0)% | (97.1, 100.0)% | (95.6, 100.0)% | (95.3, 100.0)% | (96.7, 100.0)% | (83.9, 100.0)% | (59.0, 100.0)% | | MRSE +/- 2.00 D | n/N | 133/133 | 135/135 | 127/127 | 124/124 | 117/117 | 109/109 | 21/21 | 7/7 | | | % | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | | | CI^{[1]} | (97.3, 100.0)% | (97.3, 100.0)% | (97.1, 100.0)% | (97.1, 100.0)% | (96.9, 100.0)% | (96.7, 100.0)% | (83.9, 100.0)% | (59.0, 100.0)% | | UCVA 20/20 or better | n/N | 104/133 | 108/135 | 110/127 | 118/133 | 108/117 | 95/111 | 18/21 | 5/7 | | | % | 78.2% | 80.0% | 86.6% | 88.7% | 92.3% | 85.6% | 85.7% | 71.4% | | | CI^{[1]} | (70.2, 84.9)% | (72.3, 86.4)% | (79.4, 92.0)% | (82.1, 93.5)% | (85.9, 96.4)% | (77.6, 91.5)% | (63.7, 97.0)% | (29.0, 96.3)% | | UCVA 20/40 or better | n/N | 133/133 | 135/135 | 127/127 | 133/133 | 117/117 | 111/111 | 21/21 | 7/7 | | | % | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | | | CI^{[1]} | (97.3, 100.0)% | (97.3, 100.0)% | (97.1, 100.0)% | (97.3, 100.0)% | (96.9, 100.0)% | (96.7, 100.0)% | (83.9, 100.0)% | (59.0, 100.0)% | [1] Exact 95% confidence Interval **Table 18: Primary Effectiveness Variables for All Treated Eyes** 86.6% (110/127) of eyes in this cohort achieved a postoperative uncorrected visual acuity (UCVA) of 20/20 or better at the 3-month postoperative visit. Additionally, 92.9% (118/127) study eyes were within $\pm 0.5\text{D}$ of attempted MRSE and 100% (127/127) of the eyes were within $\pm 1.0\text{D}$ of attempted MRSE at 3 months after the topography-assisted procedure. The time point to refractive stability is 3 months for the CATz-1 cohort. The summary of effectiveness variables was stratified by preoperative manifest sphere and preoperative manifest cylinder for the cohort at 3-months to encompass the time point of refractive stability. The results of this stratification are summarized in the Tables 19 and 20. | Primary Effectiveness Variables at Month 3 for All Treated Eyes by Preoperative Manifest Sphere | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | Statistic | -1.00 to -2.00 D | -2.01 to -3.00 D | -3.01 to -4.00 D | -4.01 to -5.00 D^{[2]} | -5.01 to -6.00 D^{[2]} | Total | | MRSE +/- 0.50 D | n/N | 39/41 | 22/22 | 34/35 | 14/17 | 9/12 | 118/127 | | | % | 95.1% | 100.0% | 97.1% | 82.4% | 75.0% | 92.9% | PMA P970053/S11 FDA Summary of Safety and Effectiveness Data Page 25 {25} | **Primary Effectiveness Variables at Month 3 for All Treated Eyes by Preoperative Manifest Sphere** | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | Statistic | -1.00 to -2.00 D | -2.01 to -3.00 D | -3.01 to -4.00 D | -4.01 to -5.00 D^{[2]} | -5.01 to -6.00 D^{[2]} | Total | | | CI^{[1]} | (78.6, 99.2)% | (84.6, 100.0)% | (85.1, 99.9)% | (56.6, 96.2)% | (42.8, 94.5)% | (87.0, 96.7)% | | MRSE +/- 1.00 D | n/N | 41/41 | 22/22 | 35/35 | 17/17 | 12/12 | 127/127 | | | % | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | | | CI^{[1]} | (88.8, 100.0)% | (84.6, 100.0)% | (90.0, 100.0)% | (80.5, 100.0)% | (73.5, 100.0)% | (97.1, 100.0)% | | MRSE +/- 2.00 D | n/N | 41/41 | 22/22 | 35/35 | 17/17 | 12/12 | 127/127 | | | % | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | | | CI^{[1]} | (88.8, 100.0)% | (84.6, 100.0)% | (90.0, 100.0)% | (80.5, 100.0)% | (73.5, 100.0)% | (97.1, 100.0)% | | UCVA 20/20 or better | n/N | 38/41 | 19/22 | 31/35 | 16/17 | 6/12 | 110/127 | | | % | 92.7% | 86.4% | 88.6% | 94.1% | 50.0% | 86.6% | | | CI^{[1]} | (78.6, 99.2)% | (65.1, 97.1)% | (73.3, 96.8)% | (71.3, 99.9)% | (21.1, 78.9)% | (79.4, 92.0)% | | UCVA 20/40 or better | n/N | 41/41 | 22/22 | 35/35 | 17/17 | 12/12 | 127/127 | | | % | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | | | CI^{[1]} | (88.8, 100.0)% | (84.6, 100.0)% | (90.0, 100.0)% | (80.5, 100.0)% | (73.5, 100.0)% | (97.1, 100.0)% | | [1] Exact 95% confidence Interval | | | | | | | | | [2] Outside range of approved indication for use: Flag warning | | | | | | | | **Table 19: Primary Effectiveness Variables at Month 3 for All Treated Eyes by Preoperative Manifest Sphere** | **Primary Effectiveness Variables at Month 3 for All Treated Eyes by Preoperative Manifest Cylinder** | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | Statistic | -0.50 to -0.75 D | -0.76 to -1.00 D | -1.01 to -2.00 D | -2.01 to -3.00 D^{[2]} | -3.01 to -4.00 D^{[2]} | Total | | **Effectiveness Variables** | | | | | | | | | MRSE +/- 0.50 D | n/N | 60/65 | 20/21 | 31/33 | 5/6 | 2/2 | 118/127 | | | % | 92.3% | 95.2% | 93.9% | 83.3% | 100.0% | 92.9% | | | CI^{[1]} | (83.0, 97.5)% | (76.2, 99.9)% | (79.8, 99.3)% | (35.9, 99.6)% | (15.8, 100.0)% | (87.0, 96.7)% | | MRSE +/- 1.00 D | n/N | 65/65 | 21/21 | 33/33 | 6/6 | 2/2 | 127/127 | | | % | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | | | CI^{[1]} | (94.5, 100.0)% | (83.9, 100.0)% | (89.4, 100.0)% | (54.1, 100.0)% | (15.8, 100.0)% | (97.1, 100.0)% | | MRSE +/- 2.00 D | n/N | 65/65 | 21/21 | 33/33 | 6/6 | 2/2 | 127/127 | | | % | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | PMA P970053/S11 FDA Summary of Safety and Effectiveness Data Page 26 {26} | Primary Effectiveness Variables at Month 3 for All Treated Eyes by Preoperative Manifest Cylinder | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | Statistic | -0.50 to -0.75 D | -0.76 to -1.00 D | -1.01 to -2.00 D | -2.01 to -3.00 D^{[2]} | -3.01 to -4.00 D^{[3]} | Total | | | CI^{[1]} | (94.5, 100.0)% | (83.9, 100.0)% | (89.4, 100.0)% | (54.1, 100.0)% | **(15.8, 100.0)%** | (97.1, 100.0)% | | UCVA 20/20 or better | n/N | 61/65 | 18/21 | 25/33 | 4/6 | **2/2** | 110/127 | | | % | 93.8% | 85.7% | 75.8% | 66.7% | **100.0%** | 86.6% | | | CI^{[1]} | (85.0, 98.3)% | (63.7, 97.0)% | (57.7, 88.9)% | (22.3, 95.7)% | **(15.8, 100.0)%** | (79.4, 92.0)% | | UCVA 20/40 or better | n/N | 65/65 | 21/21 | 33/33 | 6/6 | **2/2** | 127/127 | | | % | 100.0% | 100.0% | 100.0% | 100.0% | **100.0%** | 100.0% | | | CI^{[1]} | (94.5, 100.0)% | (83.9, 100.0)% | (89.4, 100.0)% | (54.1, 100.0)% | **(15.8, 100.0)%** | (97.1, 100.0)% | | [1] Exact 95% confidence Interval | | | | | | | | | [2] Outside range of approved indication for use: Flag warning | | | | | | | | | [3] Outside range of approved indication for use: Locked out | | | | | | | | **Table 20: Primary Effectiveness Variables at Month 3 for All Treated Eyes by Manifest Cylinder** ### **Change in Best Spectacle Corrected Visual Acuity (BSCVA)** Best spectacle corrected visual acuity was measured in the CATz-1 study using an early treatment diabetic retinopathy study (ETDRS) visual acuity chart. BSCVA was recorded as the total number of letters that was correctly identified by the subject. The number of letters identified was converted to lines of visual acuity by dividing the total number of letters observed by five (1 line/5 letters). Changes in the number of lines of BSCVA were then calculated. In the tables below, a decrease in lines of BSCVA represents a loss of BSCVA, whereas an increase in lines of BSCVA represents a gain or improvement in BSCVA. The changes in lines of best spectacle corrected visual acuity from screening to each postoperative visit are summarized in Table 21 for the cohort. | Changes in Lines of BCVA From Preop to Postop for All Treated Eyes | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | Statistic | Week 1 | Month 1 | Month 3 | Month 6 | Month 9 | Month 12 | Month 18 | Month 24 | | Decrease > 2 lines | n/N | 0/131 | 0/133 | 0/123 | 0/127 | 0/109 | 0/103 | 0/21 | 0/6 | | | % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | | | CI^{[1]} | (0.0, 2.8)% | (0.0, 2.7)% | (0.0, 3.0)% | (0.0, 2.9)% | (0.0, 3.3)% | (0.0, 3.5)% | (0.0, 16.1)% | (0.0, 45.9)% | | Decrease 2 lines | n/N | 0/131 | 0/133 | 2/123 | 0/127 | 0/109 | 0/103 | 0/21 | 0/6 | | | % | 0.0% | 0.0% | 1.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | | | CI^{[1]} | (0.0, 2.8)% | (0.0, 2.7)% | (0.2, 5.8)% | (0.0, 2.9)% | (0.0, 3.3)% | (0.0, 3.5)% | (0.0, 16.1)% | (0.0, 45.9)% | | Decrease 1 line | n/N | 13/131 | 12/133 | 8/123 | 4/127 | 7/109 | 9/103 | 4/21 | 0/6 | | | % | 9.9% | 9.0% | 6.5% | 3.1% | 6.4% | 8.7% | 19.0% | 0.0% | PMA P970053/S11 FDA Summary of Safety and Effectiveness Data Page 27 {27} | Changes in Lines of BCVA From Preop to Postop for All Treated Eyes | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | Statistic | Week 1 | Month 1 | Month 3 | Month 6 | Month 9 | Month 12 | Month 18 | Month 24 | | | CI^{[1]} | (5.4, 16.4)% | (4.7, 15.2)% | (2.8, 12.4)% | (0.9, 7.9)% | (2.6, 12.8)% | (4.1, 15.9)% | (5.4, 41.9)% | (0.0, 45.9)% | | No change | n/N | 57/131 | 57/133 | 43/123 | 65/127 | 45/109 | 38/103 | 5/21 | 0/6 | | | % | 43.5% | 42.9% | 35.0% | 51.2% | 41.3% | 36.9% | 23.8% | 0.0% | | | CI^{[1]} | (34.9, 52.4)% | (34.3, 51.7)% | (26.6, 44.1)% | (42.2, 60.1)% | (31.9, 51.1)% | (27.6, 47.0)% | (8.2, 47.2)% | (0.0, 45.9)% | | Increase 1 line | n/N | 50/131 | 49/133 | 44/123 | 38/127 | 33/109 | 34/103 | 4/21 | 0/6 | | | % | 38.2% | 36.8% | 35.8% | 29.9% | 30.3% | 33.0% | 19.0% | 0.0% | | | CI^{[1]} | (29.8, 47.1)% | (28.6, 45.6)% | (27.3, 44.9)% | (22.1, 38.7)% | (21.8, 39.8)% | (24.1, 43.0)% | (5.4, 41.9)% | (0.0, 45.9)% | | Increase 2 lines | n/N | 10/131 | 14/133 | 22/123 | 16/127 | 21/109 | 15/103 | 7/21 | 6/6 | | | % | 7.6% | 10.5% | 17.9% | 12.6% | 19.3% | 14.6% | 33.3% | 100.0% | | | CI^{[1]} | (3.7, 13.6)% | (5.9, 17.0)% | (11.6, 25.8)% | (7.4, 19.7)% | (12.3, 27.9)% | (8.4, 22.9)% | (14.6, 57.0)% | (54.1, 100.0)% | | Increase > 2 lines | n/N | 1/131 | 1/133 | 4/123 | 4/127 | 3/109 | 7/103 | 1/21 | 0/6 | | | % | 0.8% | 0.8% | 3.3% | 3.1% | 2.8% | 6.8% | 4.8% | 0.0% | | | CI^{[1]} | (0.0, 4.2)% | (0.0, 4.1)% | (0.9, 8.1)% | (0.9, 7.9)% | (0.6, 7.8)% | (2.8, 13.5)% | (0.1, 23.8)% | (0.0, 45.9)% | [1] Exact 95% confidence Interval **Table 21:** Changes in Lines of BCVA From Preop to Postop for All Treated Eyes Two eyes (2/123, 1.6%) had a transient two-line loss in BSCVA at the 3-month postoperative visit and none of the eyes had a two or more line loss at any other postoperative visit. 56.9% (70/123) eyes gained at least one or more lines of BSCVA. Both eyes of one subject had a transient 2-line loss of BSCVA at the 3-month postoperative visit, resulting in a BSCVA of 20/32. Data documented in the database indicates that at the 3-month postoperative visit, this study subject had 1+ PEK (Punctate Epithelial Keratitis) as well as a few meibomian gland secretions in the right eye. BSCVA at the 1-month postoperative visit was 20/20 in the right eye (OD) and 20/16 in the left eye (OS). At the 6, 9 and 12-month postoperative visits, the BSCVA was 20/20 OU. ### Uncorrected Visual Acuity Uncorrected visual acuity was measured using an ETDRS visual acuity chart. Uncorrected visual acuity across time is summarized in Table 22. Eyes treated for myopic astigmatism with CATz topography-assisted LASIK uncorrected visual outcomes at the 3-month postoperative visit were: 86.6% (110/127) eyes achieving an UCVA of 20/20 or better; 48.8% (62/127) eyes achieving an UCVA of 20/16 or better; and 7.9% (10/127) eyes achieving an UCVA of 20/12.5 or better. 99.2% (126/137) reported an UCVA of 20/32 or better, and 100% (127/127) reported an UCVA of 20/40 or better at the 3-month postoperative visit. | UCVA for All Treated Eyes | | --- | PMA P970053/S11 FDA Summary of Safety and Effectiveness Data Page 28 {28} | | Statistic | Preop | Month 1 | Month 3 | Month 6 | Month 9 | Month 12 | Month 18 | Month 24 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 20/12.5 or better | n/N | 0/135 | 8/135 | 10/127 | 10/133 | 22/117 | 17/111 | 2/21 | 0/7 | | | % | 0.0% | 5.9% | 7.9% | 7.5% | 18.8% | 15.3% | 9.5% | 0.0% | | | CI^{[1]} | (0.0, 2.7)% | (2.6, 11.3)% | (3.8, 14.0)% | (3.7, 13.4)% | (12.2, 27.1)% | (9.2, 23.4)% | (1.2, 30.4)% | (0.0, 41.0)% | | 20/16 or better | n/N | 0/135 | 45/135 | 62/127 | 65/133 | 57/117 | 57/111 | 10/21 | 3/7 | | | % | 0.0% | 33.3% | 48.8% | 48.9% | 48.7% | 51.4% | 47.6% | 42.9% | | | CI^{[1]} | (0.0, 2.7)% | (25.5, 42.0)% | (39.9, 57.8)% | (40.1, 57.7)% | (39.4, 58.1)% | (41.7, 61.0)% | (25.7, 70.2)% | (9.9, 81.6)% | | 20/20 or better | n/N | 1/135 | 108/135 | 110/127 | 118/133 | 108/117 | 95/111 | 18/21 | 5/7 | | | % | 0.7% | 80.0% | 86.6% | 88.7% | 92.3% | 85.6% | 85.7% | 71.4% | | | CI^{[1]} | (0.0, 4.1)% | (72.3, 86.4)% | (79.4, 92.0)% | (82.1, 93.5)% | (85.9, 96.4)% | (77.6, 91.5)% | (63.7, 97.0)% | (29.0, 96.3)% | | 20/25 or better | n/N | 1/135 | 130/135 | 123/127 | 127/133 | 113/117 | 106/111 | 19/21 | 5/7 | | | % | 0.7% | 96.3% | 96.9% | 95.5% | 96.6% | 95.5% | 90.5% | 71.4% | | | CI^{[1]} | (0.0, 4.1)% | (91.6, 98.8)% | (92.1, 99.1)% | (90.4, 98.3)% | (91.5, 99.1)% | (89.8, 98.5)% | (69.6, 98.8)% | (29.0, 96.3)% | | 20/32 or better | n/N | 3/135 | 132/135 | 126/127 | 133/133 | 117/117 | 111/111 | 19/21 | 5/7 | | | % | 2.2% | 97.8% | 99.2% | 100.0% | 100.0% | 100.0% | 90.5% | 71.4% | | | CI^{[1]} | (0.5, 6.4)% | (93.6, 99.5)% | (95.7, 100.0)% | (97.3, 100.0)% | (96.9, 100.0)% | (96.7, 100.0)% | (69.6, 98.8)% | (29.0, 96.3)% | | 20/40 or better | n/N | 7/135 | 135/135 | 127/127 | 133/133 | 117/117 | 111/111 | 21/21 | 7/7 | | | % | 5.2% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | | | CI^{[1]} | (2.1, 10.4)% | (97.3, 100.0)% | (97.1, 100.0)% | (97.3, 100.0)% | (96.9, 100.0)% | (96.7, 100.0)% | (83.9, 100.0)% | (59.0, 100.0)% | | 20/80 or better | n/N | 22/135 | 135/135 | 127/127 | 133/133 | 117/117 | 111/111 | 21/21 | 7/7 | | | % | 16.3% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | | | CI^{[1]} | (10.5, 23.6)% | (97.3, 100.0)% | (97.1, 100.0)% | (97.3, 100.0)% | (96.9, 100.0)% | (96.7, 100.0)% | (83.9, 100.0)% | (59.0, 100.0)% | | 20/200 or better | n/N | 135/135 | 135/135 | 127/127 | 133/133 | 117/117 | 111/111 | 21/21 | 7/7 | | | % | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | | | CI^{[1]} | (97.3, 100.0)% | (97.3, 100.0)% | (97.1, 100.0)% | (97.3, 100.0)% | (96.9, 100.0)% | (96.7, 100.0)% | (83.9, 100.0)% | (59.0, 100.0)% | [1] Exact 95% confidence Interval **Table 22: UCVA for All Treated Eyes** Eyes treated in the study also showed improvement in functional vision after the topography-assisted LASIK procedure. As shown in Table 23, 20.4% (26/127) of study eyes reported an uncorrected visual acuity at 3-months of at least one line less than the baseline best spectacle corrected visual acuity (BSCVA) before CATz-1 LASIK treatment; and 79.5% (101/127) of study eyes achieved an uncorrected visual acuity at 3-months equal to or greater than the baseline BSCVA before CATz-1 LASIK treatment. Postop UCVA Compared to Preop BCVA for All Treated Eyes PMA P970053/S11 FDA Summary of Safety and Effectiveness Data Page 29 {29} | | Statistic | Week 1 | Month 1 | Month 3 | Month 6 | Month 9 | Month 12 | Month 18 | Month 24 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | > 2 lines better | n/N | 0/133 | 1/135 | 1/127 | 1/133 | 2/117 | 6/111 | 0/21 | 0/7 | | | % | 0.0% | 0.7% | 0.8% | 0.8% | 1.7% | 5.4% | 0.0% | 0.0% | | | CI^{[1]} | (0.0, 2.7)% | (0.0, 4.1)% | (0.0, 4.3)% | (0.0, 4.1)% | (0.2, 6.0)% | (2.0, 11.4)% | (0.0, 16.1)% | (0.0, 41.0)% | | 2 lines better | n/N | 8/133 | 6/135 | 15/127 | 15/133 | 19/117 | 14/111 | 7/21 | 1/7 | | | % | 6.0% | 4.4% | 11.8% | 11.3% | 16.2% | 12.6% | 33.3% | 14.3% | | | CI^{[1]} | (2.6, 11.5)% | (1.6, 9.4)% | (6.8, 18.7)% | (6.5, 17.9)% | (10.1, 24.2)% | (7.1, 20.3)% | (14.6, 57.0)% | (0.4, 57.9)% | | 1 line better | n/N | 33/133 | 41/135 | 47/127 | 46/133 | 37/117 | 31/111 | 3/21 | 4/7 | | | % | 24.8% | 30.4% | 37.0% | 34.6% | 31.6% | 27.9% | 14.3% | 57.1% | | | CI^{[1]} | (17.7, 33.0)% | (22.8, 38.9)% | (28.6, 46.0)% | (26.6, 43.3)% | (23.3, 40.9)% | (19.8, 37.2)% | (3.0, 36.3)% | (18.4, 90.1)% | | Equal | n/N | 56/133 | 53/135 | 38/127 | 49/133 | 40/117 | 39/111 | 5/21 | 0/7 | | | % | 42.1% | 39.3% | 29.9% | 36.8% | 34.2% | 35.1% | 23.8% | 0.0% | | | CI^{[1]} | (33.6, 51.0)% | (31.0, 48.0)% | (22.1, 38.7)% | (28.6, 45.6)% | (25.7, 43.5)% | (26.3, 44.8)% | (8.2, 47.2)% | (0.0, 41.0)% | | 1 line worse | n/N | 22/133 | 29/135 | 20/127 | 17/133 | 16/117 | 17/111 | 4/21 | 0/7 | | | % | 16.5% | 21.5% | 15.7% | 12.8% | 13.7% | 15.3% | 19.0% | 0.0% | | | CI^{[1]} | (10.7, 24.0)% | (14.9, 29.4)% | (9.9, 23.3)% | (7.6, 19.7)% | (8.0, 21.3)% | (9.2, 23.4)% | (5.4, 41.9)% | (0.0, 41.0)% | | 2 lines worse | n/N | 10/133 | 3/135 | 5/127 | 4/133 | 2/117 | 2/111 | 0/21 | 2/7 | | | % | 7.5% | 2.2% | 3.9% | 3.0% | 1.7% | 1.8% | 0.0% | 28.6% | | | CI^{[1]} | (3.7, 13.4)% | (0.5, 6.4)% | (1.3, 8.9)% | (0.8, 7.5)% | (0.2, 6.0)% | (0.2, 6.4)% | (0.0, 16.1)% | (3.7, 71.0)% | | > 2 lines worse | n/N | 4/133 | 2/135 | 1/127 | 1/133 | 1/117 | 2/111 | 2/21 | 0/7 | | | % | 3.0% | 1.5% | 0.8% | 0.8% | 0.9% | 1.8% | 9.5% | 0.0% | | | CI^{[1]} | (0.8, 7.5)% | (0.2, 5.2)% | (0.0, 4.3)% | (0.0, 4.1)% | (0.0, 4.7)% | (0.2, 6.4)% | (1.2, 30.4)% | (0.0, 41.0)% | [1] Exact 95% confidence Interval **Table 23:** Postop UCVA Compared to Preop BCVA for All Treated Eyes ### **Treatment Accuracy for Manifest Sphere and Manifest Cylinder** The descriptive statistics for the predictability (accuracy) of the attempted versus achieved manifest sphere and magnitude of cylinder are summarized in Table 24 for this cohort of myopic astigmatic eyes. PMA P970053/S11 FDA Summary of Safety and Effectiveness Data Page 30 {30} At the timepoint of refractive stability (3-months), the eyes in the entire myopic astigmatic cohort (see table below) achieved at least 72% of the attempted magnitude of cylinder treatment and 103% of the attempted spherical treatment. The percentage of magnitude of cylinder achieved remains constant through the 18-month visit, as does the percentage of spherical treatment achieved. 92% of study eyes were within $\pm 0.50\text{D}$ of the attempted magnitude of cylinder treatment at the 3-month visit. | Treatment Accuracy for Sphere and Cylinder Magnitude for All Treated Eyes | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | Preop | Week 1 | Month 1 | Month 3 | Month 6 | Month 9 | Month 12 | Month 18 | Month 24 | | **Sphere** | N = 135 | N = 133 | N = 135 | N = 127 | N = 133 | N = 117 | N = 111 | N = 21 | N = 7 | | Mean (SD) | -3.06 (1.40) | 0.11 (0.38) | 0.08 (0.31) | 0.06 (0.31) | 0.05 (0.32) | 0.03 (0.33) | 0.02 (0.37) | 0.11 (0.35) | 0.07 (0.35) | | Attempted (SD) | -3.06 (1.40) | -3.08 (1.39) | -3.06 (1.40) | -3.04 (1.43) | -3.05 (1.41) | -3.04 (1.40) | -3.22 (1.41) | -3.83 (1.62) | -3.96 (1.43) | | Achieved (SD) | | -3.19 (1.52) | -3.13 (1.44) | -3.10 (1.48) | -3.10 (1.46) | -3.07 (1.45) | -3.24 (1.45) | -3.94 (1.61) | -4.04 (1.57) | | % Achieved | | 103 | 103 | 103 | 102 | 102 | 101 | 105 | 101 | | Within +/- 0.5D, n (%) | | 115 (86%) | 127 (94%) | 121 (95%) | 124 (93%) | 109 (93%) | 100 (90%) | 19 (90%) | 7 (100%) | | Within +/- 1.0D, n (%) | | 131 (98%) | 134 (99%) | 126 (99%) | 133 (100%) | 117 (100%) | 111 (100%) | 21 (100%) | 7 (100%) | | **Cylinder** | N = 135 | N = 133 | N = 135 | N = 127 | N = 133 | N = 117 | N = 111 | N = 21 | N = 7 | | Mean (SD) | -1.03 (0.64) | -0.21 (0.27) | -0.23 (0.25) | -…